Supported by an educational grant from Neurocrine Biosciences, Inc.

Posters

Patient Perspective on Barriers to Diagnosis and Treatment of Tardive Dyskinesia: Results From a Cross-Sectional Survey

Tardive dyskinesia (TD) is a hyperkinetic movement disorder resulting from chronic exposure to antipsychotics.

All Posters

Impact of Tardive Dyskinesia on Clinical Aspects and Quality of Life Based on Individuals’ Underlying Psychiatric Conditions: Interim Analysis of Baseline Data From the IMPACT-TD Registry

There is limited understanding of how tardive dyskinesia (TD) affects individuals with different underlying psychiatric conditions.

Once-Daily Valbenazine for Tardive Dyskinesia or Huntington’s Disease Chorea in Patients with Dysphagia or Swallowing Difficulties

Once-daily valbenazine is approved for tardive dyskinesia (TD) and Huntington’s disease (HD) chorea.

Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment

Valbenazine is a once-daily medication approved for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington’s disease.

A Multi-Year Survey on United States Psychiatry Clinicians: Trends on Managing Patients with Tardive Dyskinesia

Tardive dyskinesia (TD) can profoundly impact patients’ daily functioning and overall quality of life, making appropriate diagnosis and management critical.

Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease: A Post-Hoc Analysis of Phase 3 Data and Magnitude of Effect

Once-daily valbenazine is approved for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD).

Real World Improvement in Quality of Life and Functional Status of Valbenazine-Treated Patients With Tardive Dyskinesia From a 2024 Chart Extraction and Clinician Survey of 164 Patients

Tardive dyskinesia (TD) significantly impacts quality of life (QoL) beyond movement symptoms.

Longitudinal change in the items of the Tardive Dyskinesia Impact Scale (TDIS), a disease-specific, patient-reported outcome measure using data from KINECT®3 (NCT02274558) and KINECT®4 (NCT02405091)

Tardive dyskinesia (TD) is a potentially disabling involuntary movement disorder due to dopamine receptor-blocking agent exposure and can impair physical, psychological, functional, and socio-emoti

Impact of valbenazine on physical, psychological, and functional health in 127 patients with tardive dyskinesia: results of EQ-5D-5L health state scores from a double-blind, placebo-controlled, randomized withdrawal phase 4 study

Tardive dyskinesia (TD) is a movement disorder associated with prolonged exposure to dopamine receptor blocking agents that can significantly impact one’s quality of life (QoL).

Long-Term Efficacy and Safety of Deutetrabenazine in Patients With Tardive Dyskinesia: Post Hoc Subgroup Analysis by Race

Deutetrabenazine demonstrated clinically significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores in 12-week pivotal tardive dyskinesia (TD) trials (ARM-TD [NCT02195700]/AIM-TD